Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

- PMLiVE

Merck & Co’s sugammadex delayed in US

FDA says it needs more time to review application

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

Informatics to drive clinical trials in UK

Scotland’s chief scientist says NHS data can support medicines research

- PMLiVE

Former Amgen R&D head Perlmutter to lead research at Merck & Co

Returns to US pharma firm after more than a decade away

- PMLiVE

Discount convinces NICE to uphold recommendation for Novartis’ Xolair

Asthma drug now also available for children

Novartis building

Novartis’ Ilaris cleared for gouty arthritis in EU

First biologic drug approved for condition in Europe

- PMLiVE

Novartis provides multimedia support to Rare Diseases Day

Collaborates with Eurordis on multimedia education campaign

- PMLiVE

UCB CEO: Patient info more important than transparency

Roch Doliveux says misinformation is the “worst thing that can happen in healthcare”

- PMLiVE

UCB says new medicines drive growth in 2012

Also optimistic about its late-stage pipeline

Roche - Basel

Roche promises greater access to clinical trial data

Company critics say measures do not go far enough

Novartis to expand SMS for Life approach across Africa

Will broaden reach of mobile-based medicines management programme 

- PMLiVE

Novartis gives Vasella honorary role as payout row continues

Named honorary chairman chairman at Swiss pharma firm after stepping down as chairman

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links